Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels

Maryam Mahmood, Omar Abu Saleh, M. Rizwan Sohail
Maryam Mahmood
Division of Infectious Disease, Mayo Clinic, Rochester, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omar Abu Saleh
Division of Infectious Disease, Mayo Clinic, Rochester, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Rizwan Sohail
Division of Infectious Disease, Mayo Clinic, Rochester, Minnesota, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00019-17
  • Article
  • Info & Metrics
  • PDF
Loading

LETTER

We report a case of posaconazole toxicity in a 44-year-old man with a history of diffuse large B cell lymphoma. He achieved disease remission following 4 cycles of chemotherapy, with the last cycle administered over a year prior to presentation. He presented with several weeks of fatigue, nonproductive cough, fever, and night sweats. 18F-fluoro-deoxyglucose (FDG) positron emission computed tomography demonstrated numerous FDG-avid pulmonary nodules and mediastinal and bilateral hilar adenopathy without evidence of recurrent lymphoma at the site of prior nasal involvement. Granulomatous inflammation was present upon mediastinal lymph node biopsy. Histoplasma antibody complement fixation and histoplasma urine antigen levels were consistent with pulmonary histoplasmosis. The patient was initially started on itraconazole. However, he developed generalized pruritus and an urticarial rash 5 days after starting itraconazole. The rash resolved after itraconazole was stopped. Skin testing was negative for posaconazole, fluconazole, and voriconazole. Therefore, the patient was switched to posaconazole delayed-release tablets (300 mg daily), which he tolerated without issues. A serum posaconazole level measured 2 weeks after initiation of therapy was 7,980 ng/ml; therefore, the posaconazole dose was decreased to 200 mg daily. Two months after initiating antifungal therapy, he developed fatigue, polyuria, and hypertension, with a blood pressure of 154/98 mm Hg. Serum chemistries were notable for potassium at 2.2 mmol/liter and a posaconazole level of 5,180 ng/ml. Laboratory studies were notable for mild metabolic alkalosis and a urine transtubular potassium excretion gradient of 6.3%, suggestive of inappropriate renal potassium wasting. In addition, early-morning plasma renin (<0.7 ng/ml) and aldosterone (<4.0 ng/dl) levels were undetectable, with a normal early-morning serum cortisol level (17 μg/dl). No gastrointestinal or other source of potassium loss could be identified, and the patient was on no other medications. An echocardiogram (ECG) demonstrated sinus bradycardia and a prominent U wave, prompting admission for cardiac monitoring and intravenous potassium repletion. He received 290 meq of potassium and was started on oral potassium supplementation. The posaconazole dose was further decreased to 100 mg daily. A subsequent posaconazole level was measured at 2,160 ng/ml, with resolution of the alkalosis, hypokalemia, and hypertension.

Posaconazole is a potent, extended-spectrum triazole antifungal approved for the treatment and prophylaxis of serious fungal infections. Use of the oral-suspension formulation of posaconazole is often hindered by subtherapeutic levels due to poor absorption, and high drug levels are rarely achieved. However, with the newer delayed-release tablet formulation, more patients achieve high serum drug concentrations (1, 2). At our institution, we usually obtain posaconazole trough levels at least once after initiation, with a general goal of at least 1,000 to 1,250 ng/ml for treatment of fungal infections, based on improved response rates with higher serum drug levels in a study of salvage therapy for invasive aspergillosis. Dose adjustment is not typically required with the delayed-release tablet formulation (3). In clinical trials, hypokalemia was reported in 22% of patients who received posaconazole at 300 mg daily (4). While the precise mechanism of posaconazole-induced hypokalemia is not known, the combination of hypertension, hypokalemia, undetectable plasma renin and aldosterone levels, and a normal serum cortisol level in our patient indicate apparent mineralocorticoid excess. Similar syndromes of hypertension and hypokalemia have been reported with the structurally related azoles itraconazole and ketoconazole. Whether these azoles have a direct mineralocorticoid effect or alter mineralocorticoid enzymatic pathways remains to be determined. There has been one previous similar reported case of hypokalemia and metabolic alkalosis with a high serum posaconazole level raising concern for an association between high drug levels and observed toxicity (5).

  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Durani U,
    2. Tosh PK,
    3. Barreto JN,
    4. Estes LL,
    5. Jannetto PJ,
    6. Tande AJ
    . 2015. Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension. Antimicrob Agents Chemother59:4914–4918. doi:10.1128/AAC.00496-15.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Courtney R,
    2. Pai S,
    3. Laughlin M,
    4. Lim J,
    5. Batra V
    . 2003. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother47:2788–2795. doi:10.1128/AAC.47.9.2788-2795.2003.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Walsh TJ,
    2. Raad I,
    3. Patterson TF,
    4. Chandrasekar P,
    5. Donowitz GR,
    6. Graybill R,
    7. Greene RE,
    8. Hachem R,
    9. Hadley S,
    10. Herbrecht R,
    11. Langston A,
    12. Louie A,
    13. Ribaud P,
    14. Segal BH,
    15. Stevens DA,
    16. van Burik JA,
    17. White CS,
    18. Corcoran G,
    19. Gogate J,
    20. Krishna G,
    21. Pedicone L,
    22. Hardalo C,
    23. Perfect JR
    . 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis44:2. doi:10.1086/508774.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Merck & Co, Inc. 2014. Noxafil® package insert. Merck & Co, Inc,Whitehouse Station, NJ.
  5. 5.↵
    1. Martino J,
    2. Fisher BT,
    3. Bosse KR,
    4. Bagatell R
    . 2015. Suspected posaconazole toxicity in a pediatric oncology patient. Pediatr Blood Cancer62:1682. doi:10.1002/pbc.25568.
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels
Maryam Mahmood, Omar Abu Saleh, M. Rizwan Sohail
Antimicrobial Agents and Chemotherapy Mar 2017, 61 (4) e00019-17; DOI: 10.1128/AAC.00019-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels
Maryam Mahmood, Omar Abu Saleh, M. Rizwan Sohail
Antimicrobial Agents and Chemotherapy Mar 2017, 61 (4) e00019-17; DOI: 10.1128/AAC.00019-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • REFERENCES
  • Info & Metrics
  • PDF

KEYWORDS

antifungal agents
hypertension
hypokalemia
triazoles
fungal infections
infectious disease

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596